JPRN-UMIN000003581已完成未知
The Observational Study of De Novo Chronic Myeloid Leukemia Patients in Chronic Phase in Japan - The New Target Observational Study 1
The Japanese Society of Hematology0 个研究点目标入组 500 人开始时间: 2010年5月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients previously treated with any investigational drug for CML. 2)Patients previously treated with IFN-alpha. 3)Patients previously receiving any oral cytotoxic drug (e.g., hydroxyurea) for at least 3 months. 4)Women with confirmed or potential pregnancy, nursing mothers, and male or female patients who wish to have a child during the study period. 5)Patients with a history of allergy to imatinib. 6)Patients with any concomitant illness that contraindicates use of imatinib. 7)Patients with any other condition that, in the investigator's opinion, disqualifies them for inclusion in the study.
研究者
相似试验
已完成
不适用
The Observational Study of Chronic Myeloid Leukemia Patients in Chronic Phase with Resistance or Intolerance to Preceding TKI in JapaJPRN-UMIN000003582The Japanese Society of Hematology110
尚未招募
不适用
Chronic Myeloid LeukemiaCTRI/2021/08/035398DRREETIKA RAMANATHA
已完成
2 期
Study of Nilotinib usefulness for chronic myeloid leukemia (CML) patients with Imatinib resistant or intolerant.Chronic myeloid leukemiaJPRN-UMIN000003016Osaka CML-MRD Meeting45
进行中（未招募）
1 期
Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon a-2a (PEG-IFN) or Roferon-A in prior clinical studies.EUCTR2004-002093-30-ESF. Hoffmann-La Roche Ltd
进行中（未招募）
1 期
Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409Relapsing-remitting multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-003884-71-CZGenzyme Corporation1,248